Navigation Links
Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
Date:9/22/2007

is usually affected at a later stage in the progression of the disease than is the more commonly diagnosed carpal-metacarpal (CMC-I) joint."

The addition of the Artelon STT Spacer expands SBi's coverage in the treatment algorithm and enables surgeons to offer a complementary range of spacers for every stage in the continuum of this debilitating disease.

Mr. Viscogliosi noted that widespread use of hand-held devices is increasingly a cause of repetitive stress conditions in the thumb leading to earlier onset of arthritis and prompting more surgical procedures such as the use of Artelon spacers.

"As with other Artelon spacers, of which more than 3,500 have been implanted since 2004, benefits may include restoring joint stability, faster recovery and post-operative elimination of pain," he added.

Prior to the introduction of the Artelon Spacer, more aggressive procedures were and continue to be used as an initial surgical option. These procedures often involve removal of the trapezoidium bone and replacing it with tissue harvested from the forearm (known as an LRTI procedure) or complete fusion of the joint.

SBi estimates that more than 40,000 of these procedures are performed on arthritic thumbs annually and that the number could rise to 55,000 by 2010.

Mr. Viscogliosi added: "What these figures do not reflect is that many more patients elect not to seek surgery of any type and may rely on a combination of medication and bracing, but with Artelon technology now being offered by several hundred hand surgeons, these patients now have access to a much less aggressive form of treatment."

Artelon Spacers now offer a new, less invasive, surgical option that spares healthy bone and tissue. The Artelon(R) CMC Spacer Arthro, cleared for marketing by the FDA earlier this year, permits minimally invasive arthroscopic implantation in patients at the earliest surgical stages of the condition.

The Artelon STT Spacer introduction stems
'/>"/>

SOURCE Small Bone Innovations, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Small lumps in breast if not treated may cause long-term harm
2. Smallpox as Biological Weapons?
3. Is Smallpox Threat Real ?
4. Smallpox Vaccine May Help Fight Cervical Cancer
5. Smallpox Would Spread Rapidly
6. Problematic Use of smallpox vaccine
7. Drug Firm Offers to Donate Smallpox Vaccine
8. Small aneurysms best left untouched
9. Researchers developed world’s smallest toothbrus
10. Third generation Small pox vaccine from Cell-culture
11. Discovery of World’s smallest laser
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 2Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 3Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 4Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 5Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 6Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 7Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 8Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 2Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 3Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 4Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 5